References
- Straus SMJM, Kors JA, De Bruin ML, van der Hooft CS, Hofman A, Heeringa J, et al. Prolonged QTc interval and risk of sudden cardiac death in a population of older adults. J Am Coll Cardiol. 2006;47(2):362–367. doi:https://doi.org/10.1016/j.jacc.2005.08.067.
- De Bruyne M, Hoes A, Kors J, Hofman A, Van Bemmel J, Grobbee D. Prolonged QT interval predicts cardiac and all-cause mortality in the elderly. The Rotterdam Study. Eur Heart J. 1999;20(4):278–284. doi:https://doi.org/10.1053/euhj.1998.1276.
- Zhang Y, Post WS, Blasco-Colmenares E, Dalal D, Tomaselli GF, Guallar E. Electrocardiographic QT interval and mortality: a meta-analysis. Epidemiology. 2011;22(5):660–670. doi:https://doi.org/10.1097/EDE.0b013e318225768b.
- Albertsen PC, Klotz L, Tombal B, Grady J, Olesen TK, Nilsson J. Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist. European Urology. 2014;65(3):565–573. doi:https://doi.org/10.1016/j.eururo.2013.10.032.
- Keyes M, Merrick G, Frank S, Grimm P, Zelefsky M. American Brachytherapy Society Task Group Report: use of androgen deprivation therapy with prostate brachytherapy-a systematic literature review. Brachytherapy. 2017;16(2):245–65. doi:https://doi.org/10.1016/j.brachy.2016.11.017.
- Barber M, Nguyen LS, Wassermann J, Spano J-P, Funck-Brentano C, Salem J-E. Cardiac arrhythmia considerations of hormone cancer therapies. Cardiovasc Res. 2019;115(5):878–894. doi:https://doi.org/10.1093/cvr/cvz020.
- Hasegawa K, Ito H, Kaseno K, Miyazaki S, Shiomi Y, Tama N, et al. Impact of medical castration on malignant arrhythmias in patients with prostate cancer. JAHA. 2021;10(5):e017267. doi:https://doi.org/10.1161/JAHA.120.017267.
- Gagliano-Jucá T, Travison TG, Kantoff PW, Nguyen PL, Taplin M-E, Kibel AS, et al. Androgen deprivation therapy is associated with prolongation of QTc interval in men with prostate cancer. J Endocr Soc. 2018;2(5):485–496. doi:https://doi.org/10.1210/js.2018-00039.
- Platz EA, De Marzo AM. Epidemiology of inflammation and prostate cancer. J Urol. 2004;171(2 Pt 2):S36–S40. doi:https://doi.org/10.1097/01.ju.0000108131.43160.77.
- Gutiérrez-Cuevas J, Sandoval-Rodriguez A, Meza-Rios A, Monroy-Ramírez HC, Galicia-Moreno M, García-Bañuelos J, et al. Molecular mechanisms of obesity-linked cardiac dysfunction: an up-date on current knowledge. Cells. 2021;10(3):629. doi:https://doi.org/10.3390/cells10030629.
- Vandael E, Vandenberk B, Vandenberghe J, Willems R, Foulon V. Risk factors for QTc-prolongation: systematic review of the evidence. Int J Clin Pharm. 2017;39(1):16–25. doi:https://doi.org/10.1007/s11096-016-0414-2.
- Rautaharju PM, Surawicz B, Gettes LS, Bailey JJ, Childers R, Deal BJ, Heart Rhythm Society, et al. AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part IV: the ST segment, T and U waves, and the QT interval: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society. Endorsed by the International Society for Computerized Electrocardiology. J Am Coll Cardiol. 2009;53(11):982–991. doi:https://doi.org/10.1016/j.jacc.2008.12.014.
- Cooperberg MR, Hilton JF, Carroll PR. The CAPRA-S score: a straightforward tool for improved prediction of outcomes after radical prostatectomy. Cancer. 2011;117(22):5039–5046. doi:https://doi.org/10.1002/cncr.26169.
- Olsson H, Petri N, Erichsen L, Malmberg A, Grundemar L. Effect of degarelix, a gonadotropin-releasing hormone receptor antagonist for the treatment of prostate cancer, on cardiac repolarisation in a randomised, placebo and active comparator controlled thorough QT/QTc trial in healthy men. Clin Drug Investig. 2017;37(9):873–879. doi:https://doi.org/10.1007/s40261-017-0547-7.
- Smith MR, Klotz L, Persson B-E, Olesen TK, Wilde AA. Cardiovascular safety of degarelix: results from a 12-month, comparative, randomized, open label, parallel group phase III trial in patients with prostate cancer. J Urol. 2010;184(6):2313–2319. doi:https://doi.org/10.1016/j.juro.2010.08.012.
- Pasquier M, Pantet O, Hugli O, Pruvot E, Buclin T, Waeber G, et al. Prevalence and determinants of QT interval prolongation in medical inpatients. Intern Med J. 2012;42(8):933–940. doi:https://doi.org/10.1111/j.1445-5994.2011.02447.x.
- Ma Q, Li Z, Guo X, Guo L, Yu S, Yang H, et al. Prevalence and risk factors of prolonged corrected QT interval in general Chinese population. BMC Cardiovasc Disord. 2019;19(1):10. doi:https://doi.org/10.1186/s12872-019-1244-7.
- Leong DP, Fradet V, Shayegan B, Duceppe E, Siemens R, Niazi T, et al. Cardiovascular risk in men with prostate cancer: insights from the RADICAL PC study. J Urol. 2020;203(6):1109–1116. doi:https://doi.org/10.1097/JU.0000000000000714.
- Muniyan S, Xi L, Datta K, Das A, Teply BA, Batra SK, et al. Cardiovascular risks and toxicity – the Achilles heel of androgen deprivation therapy in prostate cancer patients. Biochim Biophys Acta Rev Cancer. 2020;1874(1):188383. doi:https://doi.org/10.1016/j.bbcan.2020.188383.
- Hu J-R, Duncan MS, Morgans AK, Brown JD, Meijers WC, Freiberg MS, et al. Cardiovascular effects of androgen deprivation therapy in prostate cancer: contemporary meta-analyses. Arterioscler Thromb Vasc Biol. 2020;40(3):e55–e64. doi:https://doi.org/10.1161/ATVBAHA.119.313046.
- Salem J-E, Yang T, Moslehi JJ, Waintraub X, Gandjbakhch E, Bachelot A, et al. Androgenic effects on ventricular repolarization: a translational study from the international pharmacovigilance database to iPSC-cardiomyocytes. Circulation. 2019;140(13):1070–1080. doi:https://doi.org/10.1161/CIRCULATIONAHA.119.040162.
- Pickles T, Tyldesley S, Hamm J, Virani SA, Morris WJ, Keyes M. Brachytherapy for intermediate-risk prostate cancer, androgen deprivation, and the risk of death. Int J Radiat Oncol Biol Phys. 2018;100(1):45–52. doi:https://doi.org/10.1016/j.ijrobp.2017.08.042.
- D'Amico AV, Chen M-H, Renshaw A, Loffredo M, Kantoff PW. Long-term follow-up of a randomized trial of radiation with or without androgen deprivation therapy for localized prostate cancer. JAMA. 2015;314(12):1291–3. doi:https://doi.org/10.1001/jama.2015.8577.
- Panoulas VF, Toms TE, Douglas KMJ, Sandoo A, Metsios GS, Stavropoulos-Kalinoglou A, Kitas GD. Prolonged QTc interval predicts all-cause mortality in patients with rheumatoid arthritis: an association driven by high inflammatory burden. Rheumatology. 2014;53(1):131–137. doi:https://doi.org/10.1093/rheumatology/ket338.
- Adlan AM, Panoulas VF, Smith JP, Fisher JP, Kitas GD. Association between corrected QT interval and inflammatory cytokines in rheumatoid arthritis. J Rheumatol. 2015;42(3):421–428. doi:https://doi.org/10.3899/jrheum.140861.
- Lazzerini PE, Acampa M, Capecchi PL, Hammoud M, Maffei S, Bisogno S, et al. Association between high sensitivity C-reactive protein, heart rate variability and corrected QT interval in patients with chronic inflammatory arthritis. Eur J Intern Med. 2013;24(4):368–374. doi:https://doi.org/10.1016/j.ejim.2013.02.009.
- Lazzerini PE, Acampa M, Capecchi PL, Fineschi I, Selvi E, Moscadelli V, et al. Antiarrhythmic potential of anticytokine therapy in rheumatoid arthritis: tocilizumab reduces corrected QT interval by controlling systemic inflammation. Arthritis Care Res. 2015;67(3):332–339. doi:https://doi.org/10.1002/acr.22455.
- Gérarda A, Romania S, Fresse A, Viard D, Parassol N. HEADING: COVID-19 “off-label” use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: a survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers. Therapie. 2020;75(4):371–379. doi:https://doi.org/10.1016/j.therap.2020.05.002.
- Chang H-M, Okwuosa TM, Scarabelli T, Moudgil R, Yeh ETH. Cardiovascular complications of cancer therapy best practices in diagnosis, prevention, and management: part 2. J Am Coll Cardiol. 2017;70(20):2552–2565.
- Kligfield P, Gettes L, Bailey J, Childers R, Deal BJ, Hancock W, et al. Recommendations for the standardization and interpretation of the electrocardiogram: part I: the electrocardiogram and its technology a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; American College of Cardiology Foundation, Heart Rhythm Society. Ciculation. 2007;115:1109–1127.